Company reports record preliminary fourth quarter net revenue of $102.9 Million, contributing to a total of $301.8 Million in revenue for ...

As part of the transition to the new administration, CMS is reviewing its coverage policies for skin substitute products.

Celularity (CELU) welcomes action by the Centers for Medicare & Medicaid Services, or CMS, to revise to January 1, 2026, the effective date ...

Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcersFLORHAM PARK, N.J., April 14, 2025 ...

Medical products group Convatec has said the sales outlook for InnovaMatrix has improved after an announcement by the US ...

Shoe Technology Reduces Risk of Diabetic Foot Ulcers Apr. 19, 2024 — Researchers have developed a new shoe insole technology that helps reduce the risk of diabetic foot ulcers, a dangerous open ...

Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSCs), reported today successful results of a Phase 1/2a clinical trial for treating ...

Diabetic foot screening intervals could be extended beyond 1 year for patients at very low risk for diabetic foot complications.

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25 ...

Any condition that compromises your circulation makes you more likely to develop arterial skin ulcers. Diabetic Foot Ulcers Neuropathic skin ulcers, also called diabetic foot ulcers, are most common ...

aureus). The findings demonstrated BX211 to be safe and well-tolerated and that patients receiving BX211 exhibited statistically significant 1 and sustained reduction of ulcer size (PAR ...